JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, announced today the initiation of a study to determine the clinical binding properties of BL-1020 to the dopamine receptors in the human brain. The trial, which is being conducted following the successful filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration, is designed as a single-center, randomized, open-label, sequential cohort clinical study to be conducted at Uppsala, Sweden. The results of the study will provide further data related to the anticipated efficacy of the BL-1020 compound - the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial will also supply additional safety, tolerability and pharmacokinetic data.
